MetaCap

Atara Biotherapeutics (ATRA) vs Anavex Life Sciences (AVXL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atara Biotherapeutics (ATRA) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 53.7% versus a loss of 81.9%. Over five years, AVXL leads with a -97.0% price change compared with -98.6% for ATRA. Atara Biotherapeutics is the larger company by market cap ($64.5 million vs $54.8 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATRA-53.73%AVXL-81.86%
+70%-10%-89%
Nov 21, 20251 yearNov 20, 2026
ATRA-98.62%AVXL-97.08%
+5%-50%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATRA versus AVXL key metrics
MetricATRAAVXL
Share price$6.33$0.5915
Market cap$64.49M$54.83M
1-day change-0.16%-11.39%
YTD return-65.01%-83.38%
1-year return-53.73%-81.86%
5-year return-98.56%-96.96%
Forward P/E3.96—
EPS (TTM)$-1.12$-0.14
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$120.77M—
Revenue growth (YoY)-6.33%—
Net income (latest FY)$32.69M$-46.38M
Operating margin29.69%—
Net margin27.07%—
52-week high$19.15$5.36
52-week low$3.92$0.59
Distance from 52-week high-66.94%-88.96%
Analyst consensusbuynone
Avg. price target upside+115.96%—
Average volume35.46K1.15M
Shares outstanding10.19M92.70M
Employees1034
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATRA has outperformed AVXL by 28.1 percentage points over the past year.

About Atara Biotherapeutics

ATRA stock →

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees

About Anavex Life Sciences

AVXL stock →

Anavex Life Sciences Corp. operates as a biopharmaceutical company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

ATRA vs AVXL FAQ

Which is bigger, Atara Biotherapeutics or Anavex Life Sciences?

Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $64.49M compared with $54.83M for Anavex Life Sciences (AVXL).

Which stock has performed better over the past year, ATRA or AVXL?

ATRA returned -53.73% over the past 12 months, compared with -81.86% for AVXL (price return, excluding dividends). Past performance does not predict future results.

Are Atara Biotherapeutics and Anavex Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons